Related Experiment Videos
Juvenile dermatomyositis: recognition and treatment
1Division of Rheumatology, Mayo Clinic, Rochester, Minnesota 55905, USA. reed.ann81@mayo.edu
Paediatric Drugs
|May 8, 2002
Summary
Juvenile dermatomyositis (JDM) treatment is evolving. Early use of immunomodulatory agents like methotrexate with corticosteroids improves outcomes and reduces steroid dependence in JDM patients.
Area of Science:
- Pediatric Rheumatology
- Dermatology
- Immunology
Background:
- Juvenile dermatomyositis (JDM) is a multisystem autoimmune disease affecting muscles and skin.
- Characterized by inflammation, vasculopathy, and potential calcinosis.
- Limited therapeutic options historically, with a focus on corticosteroids.
Purpose of the Study:
- To review traditional and emerging treatment regimens for JDM.
- To highlight the benefits of early immunomodulatory agent use.
- To discuss novel biologic therapies in development.
Main Methods:
- Review of current literature on JDM treatment.
- Analysis of traditional therapies including corticosteroids.
- Evaluation of newer immunomodulatory and biologic agents.
Main Results:
- Corticosteroids are a traditional mainstay, but short-term IV use shows limited long-term benefit.
- Early methotrexate use with corticosteroids accelerates recovery and allows steroid dose reduction.
- Other immunomodulators like cyclosporine and IVIG show promise in resistant cases.
Conclusions:
- Early intervention with immunomodulators like methotrexate is crucial for better JDM outcomes.
- Novel biologic therapies targeting TNF-alpha and other pathways show potential.
- Optimizing JDM treatment requires a shift towards earlier, multi-agent strategies.